Jolien Schaeverbeke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jolien Schaeverbeke has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Rik Vandenberghe
KU Leuven
17 shared publications Rik Vandenberghe
Department of Neurosciences, Laboratory for Cognitive Neurology Leuven Brain Institute, KU Leuven Leuven Belgium
16 shared publicationsKoen Van Laere
Division of Nuclear Medicine UZ Leuven Leuven Belgium
12 shared publicationsKatarzyna Adamczuk
Laboratory for Cognitive Neurology, KU Leuven Leuven Belgium
9 shared publications- Rose Bruffaerts
University of Antwerp
9 shared publications Eva Dries
Neurology Department, University Hospitals Leuven, Leuven, Belgium
7 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1041
Multimodal Retinal Imaging for the Detection of Early Alzheimer’s Disease: Combining Biochemical, Structural, and Vascular Biomarkers
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging—hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)—can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ− cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell–inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for an exploratory cross-sectional comparison across disease-stage groups. HSI showed nominally lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (AUC = 0.72). GC-IPL thickness showed a similar inferior-predominant regional pattern. Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), although this improvement over the unimodal models did not reach statistical significance, whereas vascular biomarkers contributed minimally. In an exploratory cross-sectional comparison across AD stage groups drawn from two cohorts, HSI features showed a non-monotonic pattern, decreasing in early Aβ+ stages and rising again in dementia. These findings provide preliminary evidence of complementary information between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.
- 8 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1041
Open AccessMultimodal Retinal Imaging for the Detection of Early Alzheimer’s Disease: Combining Biochemical, Structural, and Vascular Biomarkers
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging—hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)—can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ− cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell–inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for an exploratory cross-sectional comparison across disease-stage groups. HSI showed nominally lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (AUC = 0.72). GC-IPL thickness showed a similar inferior-predominant regional pattern. Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), although this improvement over the unimodal models did not reach statistical significance, whereas vascular biomarkers contributed minimally. In an exploratory cross-sectional comparison across AD stage groups drawn from two cohorts, HSI features showed a non-monotonic pattern, decreasing in early Aβ+ stages and rising again in dementia. These findings provide preliminary evidence of complementary information between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.
- Open Access
- 17 August 2026
- Published by MDPI AG in Preprints.org
Multimodal Retinal Imaging for the Detection of Early Alzheimer’s Disease: Combining Biochemical, Structural, and Vascular Biomarkers
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging—hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)—can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ− cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell–inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for exploratory trajectory analyses. HSI showed significantly lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (p = 0.01, AUC = 0.72), and GC-IPL thickness confirmed an “inferior vulnerability zone.” Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), whereas vascular biomarkers contributed minimally. HSI features followed a non-monotonic trajectory across the AD continuum, decreasing in early Aβ+ stages and rising again in dementia. These findings demonstrate synergy between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.
- 17 August 2026
- Published by MDPI AG in Preprints.org
Open AccessMultimodal Retinal Imaging for the Detection of Early Alzheimer’s Disease: Combining Biochemical, Structural, and Vascular Biomarkers
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging—hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)—can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ− cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell–inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for exploratory trajectory analyses. HSI showed significantly lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (p = 0.01, AUC = 0.72), and GC-IPL thickness confirmed an “inferior vulnerability zone.” Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), whereas vascular biomarkers contributed minimally. HSI features followed a non-monotonic trajectory across the AD continuum, decreasing in early Aβ+ stages and rising again in dementia. These findings demonstrate synergy between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.
- Open Access
- 2 July 2026
- Published by Elsevier in NeuroImage
- Vol. 338, 122098
Volumetric postmortem MRI of the medial temporal lobe in Alzheimer’s disease and related disorders: methodological advances and implications for in vivo biomarker development
- 2 July 2026
- Published by Elsevier in NeuroImage
- Vol. 338, 122098
Open AccessVolumetric postmortem MRI of the medial temporal lobe in Alzheimer’s disease and related disorders: methodological advances and implications for in vivo biomarker development
- Open Access
Blood-based multivariate methylation risk score for cognitive impairment and dementia
INTRODUCTION: Given the established association between DNA methylation and the pathophysiology of dementia and its plausible role as a molecular mediator of lifestyle and environment, blood-derived DNA methylation data could enable early detection of dementia risk. METHODS: In conjunction with an extensive array of machine learning techniques, we employed whole blood genome-wide DNA methylation data as a surrogate for 14 modifiable and non-modifiable factors in the assessment of dementia risk in two independent cohorts of Alzheimer's disease (AD) and Parkinson's disease (PD). RESULTS: We established a multivariate methylation risk score (MMRS) to identify the status of mild cognitive impairment (MCI) cross-sectionally, independent of age and sex. We further demonstrated significant predictive capability of this score for the prospective onset of cognitive decline in AD and PD. DISCUSSION: Our work shows the potential of employing blood-derived DNA methylation data in the assessment of dementia risk.
Open AccessBlood-based multivariate methylation risk score for cognitive impairment and dementia
INTRODUCTION: Given the established association between DNA methylation and the pathophysiology of dementia and its plausible role as a molecular mediator of lifestyle and environment, blood-derived DNA methylation data could enable early detection of dementia risk. METHODS: In conjunction with an extensive array of machine learning techniques, we employed whole blood genome-wide DNA methylation data as a surrogate for 14 modifiable and non-modifiable factors in the assessment of dementia risk in two independent cohorts of Alzheimer's disease (AD) and Parkinson's disease (PD). RESULTS: We established a multivariate methylation risk score (MMRS) to identify the status of mild cognitive impairment (MCI) cross-sectionally, independent of age and sex. We further demonstrated significant predictive capability of this score for the prospective onset of cognitive decline in AD and PD. DISCUSSION: Our work shows the potential of employing blood-derived DNA methylation data in the assessment of dementia risk.
- Open Access
- 22 September 2022
- Published by MIT Press in Neurobiology of Language
- Vol. 3 (4) , 515-537
Left Frontal White Matter Links to Rhythm Processing Relevant to Speech Production in Apraxia of Speech
Recent mechanistic models argue for a key role of rhythm processing in both speech production and speech perception. Patients with the non-fluent variant (NFV) of primary progressive aphasia (PPA) with apraxia of speech (AOS) represent a specific study population in which this link can be examined. Previously, we observed impaired rhythm processing in NFV with AOS. We hypothesized that a shared neurocomputational mechanism structures auditory input (sound and speech) and output (speech production) in time, a “temporal scaffolding” mechanism. Since considerable white matter damage is observed in NFV, we test here whether white matter changes are related to impaired rhythm processing. Forty-seven participants performed a psychoacoustic test battery: 12 patients with NFV and AOS, 11 patients with the semantic variant of PPA, and 24 cognitively intact age- and education-matched controls. Deformation-based morphometry was used to test whether white matter volume correlated to rhythmic abilities. In 34 participants, we also obtained tract-based metrics of the left Aslant tract, which is typically damaged in patients with NFV. Nine out of 12 patients with NFV displayed impaired rhythmic processing. Left frontal white matter atrophy adjacent to the supplementary motor area (SMA) correlated with poorer rhythmic abilities. The structural integrity of the left Aslant tract also correlated with rhythmic abilities. A colocalized and perhaps shared white matter substrate adjacent to the SMA is associated with impaired rhythmic processing and motor speech impairment. Our results support the existence of a temporal scaffolding mechanism structuring perceptual input and speech output.
- 22 September 2022
- Published by MIT Press in Neurobiology of Language
- Vol. 3 (4) , 515-537
Open AccessLeft Frontal White Matter Links to Rhythm Processing Relevant to Speech Production in Apraxia of Speech
Recent mechanistic models argue for a key role of rhythm processing in both speech production and speech perception. Patients with the non-fluent variant (NFV) of primary progressive aphasia (PPA) with apraxia of speech (AOS) represent a specific study population in which this link can be examined. Previously, we observed impaired rhythm processing in NFV with AOS. We hypothesized that a shared neurocomputational mechanism structures auditory input (sound and speech) and output (speech production) in time, a “temporal scaffolding” mechanism. Since considerable white matter damage is observed in NFV, we test here whether white matter changes are related to impaired rhythm processing. Forty-seven participants performed a psychoacoustic test battery: 12 patients with NFV and AOS, 11 patients with the semantic variant of PPA, and 24 cognitively intact age- and education-matched controls. Deformation-based morphometry was used to test whether white matter volume correlated to rhythmic abilities. In 34 participants, we also obtained tract-based metrics of the left Aslant tract, which is typically damaged in patients with NFV. Nine out of 12 patients with NFV displayed impaired rhythmic processing. Left frontal white matter atrophy adjacent to the supplementary motor area (SMA) correlated with poorer rhythmic abilities. The structural integrity of the left Aslant tract also correlated with rhythmic abilities. A colocalized and perhaps shared white matter substrate adjacent to the SMA is associated with impaired rhythmic processing and motor speech impairment. Our results support the existence of a temporal scaffolding mechanism structuring perceptual input and speech output.
- Open Access
- 3 May 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (5) , 734-746
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Objective: Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross‐reacts with p‐tau175. This study investigates two novel phospho‐specific assays for plasma p‐tau181 and p‐tau231 in clinical and asymptomatic AD.Methods: Plasma p‐tau species were quantified with Simoa in 44 AD patients, 40 spouse controls and an independent cohort of 151 cognitively unimpaired (CU) elderly who underwent Aβ‐PET. Simoa plasma Aβ42 measurements were available in a CU subset (N = 69). Receiver operating characteristics and Aβ‐PET associations were used to evaluate biomarker validity.Results: The novel plasma p‐tau181 and p‐tau231 assays did not show cross‐reactivity. Plasma p‐tau181 accurately detected clinical AD (area under the curve (AUC) = 0.98, 95% CI 0.95–1.00) as well as asymptomatic Aβ pathology (AUC = 0.84, 95% CI 0.76–0.92), while plasma p‐tau231 did not (AUC = 0.74, 95% CI 0.63–0.85 and 0.61, 95% CI 0.52–0.71, respectively). Plasma p‐tau181, but not p‐tau231, detected asymptomatic Aβ pathology more accurately than age, sex and APOE combined (AUC = 0.64). In asymptomatic elderly, correlations between plasma p‐tau181 and Aβ pathology were observed throughout the cerebral cortex (ρ = 0.40, p < 0.0001), with focal associations within AD‐vulnerable regions, particularly the precuneus. The plasma Aβ42/p‐tau181 ratio did not reflect asymptomatic Aβ pathology better than p‐tau181 alone.Interpretation: The novel plasma p‐tau181 assay is an accurate tool to detect clinical as well as asymptomatic AD and provides a phospho‐specific alternative to currently employed immunoassays.
- 3 May 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (5) , 734-746
Open AccessPhospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Objective: Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross‐reacts with p‐tau175. This study investigates two novel phospho‐specific assays for plasma p‐tau181 and p‐tau231 in clinical and asymptomatic AD.Methods: Plasma p‐tau species were quantified with Simoa in 44 AD patients, 40 spouse controls and an independent cohort of 151 cognitively unimpaired (CU) elderly who underwent Aβ‐PET. Simoa plasma Aβ42 measurements were available in a CU subset (N = 69). Receiver operating characteristics and Aβ‐PET associations were used to evaluate biomarker validity.Results: The novel plasma p‐tau181 and p‐tau231 assays did not show cross‐reactivity. Plasma p‐tau181 accurately detected clinical AD (area under the curve (AUC) = 0.98, 95% CI 0.95–1.00) as well as asymptomatic Aβ pathology (AUC = 0.84, 95% CI 0.76–0.92), while plasma p‐tau231 did not (AUC = 0.74, 95% CI 0.63–0.85 and 0.61, 95% CI 0.52–0.71, respectively). Plasma p‐tau181, but not p‐tau231, detected asymptomatic Aβ pathology more accurately than age, sex and APOE combined (AUC = 0.64). In asymptomatic elderly, correlations between plasma p‐tau181 and Aβ pathology were observed throughout the cerebral cortex (ρ = 0.40, p < 0.0001), with focal associations within AD‐vulnerable regions, particularly the precuneus. The plasma Aβ42/p‐tau181 ratio did not reflect asymptomatic Aβ pathology better than p‐tau181 alone.Interpretation: The novel plasma p‐tau181 assay is an accurate tool to detect clinical as well as asymptomatic AD and provides a phospho‐specific alternative to currently employed immunoassays.
- Open Access
- 1 January 2022
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 8 (1) , e12227
Lack of association between bridging integrator 1 ( BIN1 ) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
Introduction: The bridging integrator 1( BIN1) rs744373 risk polymorphism has been linked to increased [ 18 F]AV1451 signal in non‐demented older adults (ie., mild cognitive impairment [MCI] plus cognitively normal [CN] individuals). However, the association of BIN1 with in vivo tau, amyloid beta (Aβ) burden, and cognitive impairment in the asymptomatic stage of Alzheimer's disease (AD) remains unknown. Methods: The BIN1 effect on [ 18 F]AV1451 binding was evaluated in 59 cognitively normal (CN) participants (39% apolipoprotein E [ APOE ε4]) from the Flemish Prevent AD Cohort KU Leuven (F‐PACK), as well as in 66 Alzheimer's Disease Neuroimaging Initiative (ADNI) CN participants, using voxelwise and regional statistics. For comparison, 52 MCI patients from ADNI were also studied. Results: Forty‐four percent of F‐PACK participants were BIN1 rs744373 risk‐allele carriers, 21% showed high amyloid burden, and 8% had elevated [ 18 F]AV1451 binding. In ADNI, 53% and 50% of CNs and MCIs, respectively, carried the BIN1 rs744373 risk‐allele. Amyloid positivity was present in 23% of CNs and 51% of MCIs, whereas 2% of CNs and 35% of MCIs showed elevated [ 18 F]AV1451 binding. There was no significant effect of BIN1 on voxelwise or regional [ 18 F]AV1451 in F‐PACK or ADNI CNs, or in the pooled CN sample. No significant association between BIN1 and [ 18 F]AV1451 was obtained in ADNI MCI patients. However, in the MCI group, numerically higher [ 18 F]AV1451 binding was observed in the BIN1 risk‐allele group compared to the BIN1 normal group in regions corresponding to more progressed tau pathology. Discussion: We could not confirm the association between BIN1 rs744373 risk‐allele and elevated [ 18 F]AV1451 signal in CN older adults or MCI. Numerically higher [ 18 F]AV1451 binding was observed, however, in the MCI BIN1 risk‐allele group, indicating that the previously reported positive effect may be confounded by group. Therefore, when studying how the BIN1 risk polymorphism influences AD pathogenesis, a distinction should be made between asymptomatic, MCI, and dementia stages of AD.
- 1 January 2022
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 8 (1) , e12227
Open AccessLack of association between bridging integrator 1 ( BIN1 ) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
Introduction: The bridging integrator 1( BIN1) rs744373 risk polymorphism has been linked to increased [ 18 F]AV1451 signal in non‐demented older adults (ie., mild cognitive impairment [MCI] plus cognitively normal [CN] individuals). However, the association of BIN1 with in vivo tau, amyloid beta (Aβ) burden, and cognitive impairment in the asymptomatic stage of Alzheimer's disease (AD) remains unknown. Methods: The BIN1 effect on [ 18 F]AV1451 binding was evaluated in 59 cognitively normal (CN) participants (39% apolipoprotein E [ APOE ε4]) from the Flemish Prevent AD Cohort KU Leuven (F‐PACK), as well as in 66 Alzheimer's Disease Neuroimaging Initiative (ADNI) CN participants, using voxelwise and regional statistics. For comparison, 52 MCI patients from ADNI were also studied. Results: Forty‐four percent of F‐PACK participants were BIN1 rs744373 risk‐allele carriers, 21% showed high amyloid burden, and 8% had elevated [ 18 F]AV1451 binding. In ADNI, 53% and 50% of CNs and MCIs, respectively, carried the BIN1 rs744373 risk‐allele. Amyloid positivity was present in 23% of CNs and 51% of MCIs, whereas 2% of CNs and 35% of MCIs showed elevated [ 18 F]AV1451 binding. There was no significant effect of BIN1 on voxelwise or regional [ 18 F]AV1451 in F‐PACK or ADNI CNs, or in the pooled CN sample. No significant association between BIN1 and [ 18 F]AV1451 was obtained in ADNI MCI patients. However, in the MCI group, numerically higher [ 18 F]AV1451 binding was observed in the BIN1 risk‐allele group compared to the BIN1 normal group in regions corresponding to more progressed tau pathology. Discussion: We could not confirm the association between BIN1 rs744373 risk‐allele and elevated [ 18 F]AV1451 signal in CN older adults or MCI. Numerically higher [ 18 F]AV1451 binding was observed, however, in the MCI BIN1 risk‐allele group, indicating that the previously reported positive effect may be confounded by group. Therefore, when studying how the BIN1 risk polymorphism influences AD pathogenesis, a distinction should be made between asymptomatic, MCI, and dementia stages of AD.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e051036
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
Background: As first objective, we examined in a clinical, real‐life setting, the prognostic value of cerebrospinal fluid (CSF) based Amyloid Tau Neurodegeneration (ATN) classification for subsequent cognitive decline during the three years following a lumbar puncture. The secondary objective was to investigate the prognostic value of CSF biomarkers as continuous variables.Method: Retrospective data from an academic memory clinic sample of 228 patients (median age 67 (47‐85) years) were retrieved. CSF data (Innotest assays) were available in all patients and used for ATN classification: the cut‐off values were 798 pg/mL for amyloid‐beta 1‐42 (Aβ42) (A), 87 pg/mL for hyperphosphorylated tau (p181‐tau) (T), and 465 pg/mL for total tau (t‐tau) (N). A secondary analysis with ATN based on lower tau cut‐offs (p181‐tau: 58.9 pg/ml; t‐tau: 354 pg/ml) was also applied. Cognitive performance was evaluated by Mini Mental State Examination (MMSE) every 6 months over a period up to 36 months following the lumbar puncture. Linear mixed‐effects modelling was performed on non‐imputed data (minimum 3 MMSE scores) as well as on imputed data using the R packages ‘nlme’ and ‘mice’.Result: In the current sample, classification showed 32.02% A‐/T‐/N‐, 33.33% A+/T‐/N‐, 17.11% A+/T+/N+, 11.84% A+/T‐/N+, 4.39% A‐/T‐/N+ and 1.32% A‐/T+/N+ (3 cases), with the A‐/T+/N‐ and A+/T+/N‐ class being absent. Hence the latter 3 classes were excluded from further analyses. The change of MMSE relative to A‐/T‐/N‐ over a 36 months period was significant in all four ATN classes: A+/T+/N+ = ‐4.78 points on the MMSE; A‐/T‐/N+ = ‐4.76; A+/T‐/N+ = ‐2.83; A+/T‐/N‐ = ‐1.96. The earliest significant difference in slope was seen in the A+/T+/N+ class at 12 months after baseline (Figure 1A). The effect of ATN class on future cognitive decline was confirmed for a different set of CSF thresholds (Figure 1B). All individual baseline CSF biomarkers including the Aβ42/t‐tau ratio showed a significant correlation with subsequent cognitive decline, with the highest correlation seen for Aβ42/t‐tau.Conclusion: ATN classification based on CSF biomarkers has a statistically significant and clinically relevant prognostic value for the course of cognitive decline in a 3‐year period in a clinical practice setting.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e051036
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
Background: As first objective, we examined in a clinical, real‐life setting, the prognostic value of cerebrospinal fluid (CSF) based Amyloid Tau Neurodegeneration (ATN) classification for subsequent cognitive decline during the three years following a lumbar puncture. The secondary objective was to investigate the prognostic value of CSF biomarkers as continuous variables.Method: Retrospective data from an academic memory clinic sample of 228 patients (median age 67 (47‐85) years) were retrieved. CSF data (Innotest assays) were available in all patients and used for ATN classification: the cut‐off values were 798 pg/mL for amyloid‐beta 1‐42 (Aβ42) (A), 87 pg/mL for hyperphosphorylated tau (p181‐tau) (T), and 465 pg/mL for total tau (t‐tau) (N). A secondary analysis with ATN based on lower tau cut‐offs (p181‐tau: 58.9 pg/ml; t‐tau: 354 pg/ml) was also applied. Cognitive performance was evaluated by Mini Mental State Examination (MMSE) every 6 months over a period up to 36 months following the lumbar puncture. Linear mixed‐effects modelling was performed on non‐imputed data (minimum 3 MMSE scores) as well as on imputed data using the R packages ‘nlme’ and ‘mice’.Result: In the current sample, classification showed 32.02% A‐/T‐/N‐, 33.33% A+/T‐/N‐, 17.11% A+/T+/N+, 11.84% A+/T‐/N+, 4.39% A‐/T‐/N+ and 1.32% A‐/T+/N+ (3 cases), with the A‐/T+/N‐ and A+/T+/N‐ class being absent. Hence the latter 3 classes were excluded from further analyses. The change of MMSE relative to A‐/T‐/N‐ over a 36 months period was significant in all four ATN classes: A+/T+/N+ = ‐4.78 points on the MMSE; A‐/T‐/N+ = ‐4.76; A+/T‐/N+ = ‐2.83; A+/T‐/N‐ = ‐1.96. The earliest significant difference in slope was seen in the A+/T+/N+ class at 12 months after baseline (Figure 1A). The effect of ATN class on future cognitive decline was confirmed for a different set of CSF thresholds (Figure 1B). All individual baseline CSF biomarkers including the Aβ42/t‐tau ratio showed a significant correlation with subsequent cognitive decline, with the highest correlation seen for Aβ42/t‐tau.Conclusion: ATN classification based on CSF biomarkers has a statistically significant and clinically relevant prognostic value for the course of cognitive decline in a 3‐year period in a clinical practice setting.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S5)
Differential involvement of limbic and paralimbic cortex in episodic memory processing in cognitive aging and neurodegeneration
Background: A key component of cognitive aging is episodic memory decline. Here we examined to which degree structural integrity of (para)limbic cortex and amyloid load contribute to normal episodic memory variation in subjects between 50 and 80 years old using mediation analysis. The main hypothesis was that the effect of age on episodic memory would be mediated through hippocampal volume.Method: 180 community‐recruited cognitively intact older adults belonging to the Flemish Prevent Alzheimer's Disease Cohort KU Leuven (F‐PACK) cohort had cognitive test scores within norms as inclusion criterion, genotyping (APOE ε4 and BDNF), MRI and [18F]flutemetamol‐PET. Factor analysis was applied to determine the latent structure in the neuropsychological dataset. The primary factor (variance explained: 23%, Eigenvalue: 2.26) mainly contained episodic memory test scores: Buschke selective reminding (loadings: learning: 0.83, delayed‐recall: 0.96) and Rey Auditory Verbal Learning Test (0.60). Structural T1‐weigthed MRI were processed using voxel‐based morphometry. Hippocampal, entorhinal, perirhinal and parahippocampal volumes were derived by intersecting the modulated gray matter with Brainnetome parcellations. Amyloid load was quantified in a composite neocortical volume on [18F]flutemetamol SUVR with cerebellar grey matter reference. Linear regressions or Mann‐Whitney U tests investigated associations with episodic memory, which were further analyzed with bootstrapped mediation (R‐package ‘lavaan’).Result: Higher age was negatively related to lower episodic memory scores (β=‐0.066, pβ=‐0.005, pβ=‐0.003, pβ=3.80, p=0.0004) as well as entorhinal cortex volume (β=3.67, p0.12). Hence, we did not include amyloid or genotypes in further analyses. In the mediation analysis, hippocampal volume did not mediate the relation between age and episodic memory (Figure 1A). By contrast, entorhinal cortex volume did mediate the relation between age and episodic memory, however the direct path coefficient was also significant (Figure 1B). No significant indirect effects were found in the path analysis for the perirhinal cortex or parahippocampus (p>0.14).Conclusion: The effect of age on episodic memory is partly mediated by entorhinal rather than hippocampal volume in cognitive aging.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S5)
Differential involvement of limbic and paralimbic cortex in episodic memory processing in cognitive aging and neurodegeneration
Background: A key component of cognitive aging is episodic memory decline. Here we examined to which degree structural integrity of (para)limbic cortex and amyloid load contribute to normal episodic memory variation in subjects between 50 and 80 years old using mediation analysis. The main hypothesis was that the effect of age on episodic memory would be mediated through hippocampal volume.Method: 180 community‐recruited cognitively intact older adults belonging to the Flemish Prevent Alzheimer's Disease Cohort KU Leuven (F‐PACK) cohort had cognitive test scores within norms as inclusion criterion, genotyping (APOE ε4 and BDNF), MRI and [18F]flutemetamol‐PET. Factor analysis was applied to determine the latent structure in the neuropsychological dataset. The primary factor (variance explained: 23%, Eigenvalue: 2.26) mainly contained episodic memory test scores: Buschke selective reminding (loadings: learning: 0.83, delayed‐recall: 0.96) and Rey Auditory Verbal Learning Test (0.60). Structural T1‐weigthed MRI were processed using voxel‐based morphometry. Hippocampal, entorhinal, perirhinal and parahippocampal volumes were derived by intersecting the modulated gray matter with Brainnetome parcellations. Amyloid load was quantified in a composite neocortical volume on [18F]flutemetamol SUVR with cerebellar grey matter reference. Linear regressions or Mann‐Whitney U tests investigated associations with episodic memory, which were further analyzed with bootstrapped mediation (R‐package ‘lavaan’).Result: Higher age was negatively related to lower episodic memory scores (β=‐0.066, pβ=‐0.005, pβ=‐0.003, pβ=3.80, p=0.0004) as well as entorhinal cortex volume (β=3.67, p0.12). Hence, we did not include amyloid or genotypes in further analyses. In the mediation analysis, hippocampal volume did not mediate the relation between age and episodic memory (Figure 1A). By contrast, entorhinal cortex volume did mediate the relation between age and episodic memory, however the direct path coefficient was also significant (Figure 1B). No significant indirect effects were found in the path analysis for the perirhinal cortex or parahippocampus (p>0.14).Conclusion: The effect of age on episodic memory is partly mediated by entorhinal rather than hippocampal volume in cognitive aging.
- Open Access
- 2 July 2020
- Published by Wiley in Brain and Behavior
- Vol. 10 (8) , 2336-2351
Reproducibility of graph measures at the subject level using resting‐state fMRI
Introduction: Graph metrics have been proposed as potential biomarkers for diagnosis in clinical work. However, before it can be applied in a clinical setting, their reproducibility should be evaluated.Methods: This study systematically investigated the effect of two denoising pipelines and different whole‐brain network constructions on reproducibility of subject‐specific graph measures. We used the multi‐session fMRI dataset from the Brain Genomics Superstruct Project consisting of 69 healthy young adults.Results: In binary networks, the test–retest variability for global measures was large at low density irrespective of the denoising strategy or the type of correlation. Weighted networks showed very low test–retest values (and thus a good reproducibility) for global graph measures irrespective of the strategy used. Comparing the test–retest values for different strategies, there were significant main effects of the type of correlation (Pearson correlation vs. partial correlation), the (partial) correlation value (absolute vs. positive vs. negative), and weight calculation (based on the raw (partial) correlation values vs. based on transformed Z‐values). There was also a significant interaction effect between type of correlation and weight calculation. Similarly as for the binary networks, there was no main effect of the denoising pipeline.Conclusion: Our results demonstrated that normalized global graph measures based on a weighted network using the absolute (partial) correlation as weight were reproducible. The denoising pipeline and the granularity of the whole‐brain parcellation used to define the nodes were not critical for the reproducibility of normalized graph measures.
- 2 July 2020
- Published by Wiley in Brain and Behavior
- Vol. 10 (8) , 2336-2351
Open AccessReproducibility of graph measures at the subject level using resting‐state fMRI
Introduction: Graph metrics have been proposed as potential biomarkers for diagnosis in clinical work. However, before it can be applied in a clinical setting, their reproducibility should be evaluated.Methods: This study systematically investigated the effect of two denoising pipelines and different whole‐brain network constructions on reproducibility of subject‐specific graph measures. We used the multi‐session fMRI dataset from the Brain Genomics Superstruct Project consisting of 69 healthy young adults.Results: In binary networks, the test–retest variability for global measures was large at low density irrespective of the denoising strategy or the type of correlation. Weighted networks showed very low test–retest values (and thus a good reproducibility) for global graph measures irrespective of the strategy used. Comparing the test–retest values for different strategies, there were significant main effects of the type of correlation (Pearson correlation vs. partial correlation), the (partial) correlation value (absolute vs. positive vs. negative), and weight calculation (based on the raw (partial) correlation values vs. based on transformed Z‐values). There was also a significant interaction effect between type of correlation and weight calculation. Similarly as for the binary networks, there was no main effect of the denoising pipeline.Conclusion: Our results demonstrated that normalized global graph measures based on a weighted network using the absolute (partial) correlation as weight were reproducible. The denoising pipeline and the granularity of the whole‐brain parcellation used to define the nodes were not critical for the reproducibility of normalized graph measures.